Patents by Inventor SATHEESH B. RAVULA
SATHEESH B. RAVULA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230286928Abstract: Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions.Type: ApplicationFiled: June 18, 2019Publication date: September 14, 2023Applicant: Epigen Biosciences, Inc.Inventors: Graham BEATON, Fabio C. TUCCI, Satheesh B. RAVULA, Chandravadan R. SHAH, Suk Joong LEE
-
Publication number: 20230271926Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.Type: ApplicationFiled: May 10, 2023Publication date: August 31, 2023Inventors: Graham BEATON, Fabio C. TUCCI, Satheesh B. RAVULA, Stanton F. McHARDY, Francisco Xavier RUIZ, Ambrosio LOPEZ, Bismarck CAMPOS, Hua-Yu Leo WANG
-
Patent number: 11691951Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.Type: GrantFiled: July 2, 2021Date of Patent: July 4, 2023Assignee: CURTANA PHARMACEUTICALS, INC.Inventors: Graham Beaton, Fabio C. Tucci, Satheesh B. Ravula, Stanton F. McHardy, Francisco Xavier Ruiz, Ambrosio Lopez, Bismarck Campos, Hua-Yu Leo Wang
-
Patent number: 11427552Abstract: Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4?-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.Type: GrantFiled: February 7, 2020Date of Patent: August 30, 2022Assignee: Epigen Biosciences, Inc.Inventors: Graham Beaton, Fabio C. Tucci, Satheesh B. Ravula, Chandravadan R. Shah, Hiep Luu
-
Publication number: 20210347739Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.Type: ApplicationFiled: July 2, 2021Publication date: November 11, 2021Inventors: Graham BEATON, Fabio C. TUCCI, Satheesh B. RAVULA, Stanton F. McHARDY, Francisco Xavier RUIZ, Ambrosio LOPEZ, Bismarck CAMPOS, Hua-Yu Leo WANG
-
Publication number: 20210114991Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.Type: ApplicationFiled: November 20, 2020Publication date: April 22, 2021Inventors: Graham BEATON, Fabio C. TUCCI, Satheesh B. RAVULA, Stanton F. McHARDY, Francisco Xavier RUIZ, Ambrosio LOPEZ, Bismarck CAMPOS, Hua-Yu Leo WANG
-
Publication number: 20200181099Abstract: Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4?-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.Type: ApplicationFiled: February 7, 2020Publication date: June 11, 2020Applicant: EPIGEN BIOSCIENCES, INC.Inventors: Graham BEATON, Fabio C. TUCCI, Satheesh B. RAVULA, Chandravadan R. SHAH, Hiep LUU
-
Patent number: 10570103Abstract: A method for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a heterocyclic compound. The heterocyclic compound is a lysophosphatidic acid receptor ligand. Lysophosphatidic acid-dependent diseases and conditions include diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.Type: GrantFiled: June 5, 2018Date of Patent: February 25, 2020Assignee: EPIGEN BIOSCIENCES, INC.Inventors: Graham Beaton, Fabio C. Tucci, Satheesh B. Ravula, Chandravadan R. Shah, Hiep Luu
-
Patent number: 10526298Abstract: Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and nonalcoholic steatohepatitis (NASH); ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.Type: GrantFiled: June 18, 2018Date of Patent: January 7, 2020Assignee: EPIGEN BIOSCIENCES, INC.Inventors: Graham Beaton, Fabio C. Tucci, Satheesh B. Ravula, Chandravadan R. Shah, Hiep Luu
-
Publication number: 20190135767Abstract: A method for treating a lysophosphatidic acid-dependent disease or condition in a subject in need thereof is provided. The method includes administering to the subject a therapeutically effective amount of a heterocyclic compound. The heterocyclic compound is a lysophosphatidic acid receptor ligand. Lysophosphatidic acid-dependent diseases and conditions include diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.Type: ApplicationFiled: June 5, 2018Publication date: May 9, 2019Applicant: EPIGEN BIOSCIENCES, INC.Inventors: Graham BEATON, Fabio C. TUCCI, Satheesh B. RAVULA, Chandravadan R. SHAH, Hiep LUU
-
Patent number: 10227333Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.Type: GrantFiled: February 10, 2016Date of Patent: March 12, 2019Assignee: CURTANA PHARMACEUTICALS, INC.Inventors: Graham Beaton, Fabio Tucci, Satheesh B. Ravula, Hua-Yu Wang
-
Publication number: 20180297962Abstract: Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and nonalcoholic steatohepatitis (NASH); ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain.Type: ApplicationFiled: June 18, 2018Publication date: October 18, 2018Applicant: EPIGEN BIOSCIENCES, INC.Inventors: Graham Beaton, Fabio C. Tucci, Satheesh B. Ravula, Chandravadan R. Shah, Hiep Luu
-
Publication number: 20180244631Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.Type: ApplicationFiled: February 26, 2016Publication date: August 30, 2018Inventors: Graham BEATON, Fabio C. TUCCI, Satheesh B. RAVULA, Stanton F. MCHARDY, Francisco Xavier RUIZ, III, Ambrosio LOPEZ, Jr., Bismarck CAMPOS, Hua-Yu Leo WANG
-
Patent number: 10000459Abstract: Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-{4-[3-methyl-4-((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4?-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.Type: GrantFiled: March 17, 2014Date of Patent: June 19, 2018Assignee: Epigen Biosciences, Inc.Inventors: Graham Beaton, Fabio C. Tucci, Satheesh B. Ravula, Chandravadan R. Shah, Hiep Luu
-
Publication number: 20160237069Abstract: Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.Type: ApplicationFiled: February 10, 2016Publication date: August 18, 2016Inventors: Graham BEATON, Fabio TUCCI, Satheesh B. RAVULA, Hua-Yu WANG
-
Publication number: 20160228437Abstract: Provided herein are imidazopyridine compounds having an inhibitory effect on mixed lineage kinases (MLKs), methods of their synthesis, and methods of their therapeutic. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions.Type: ApplicationFiled: April 20, 2016Publication date: August 11, 2016Inventors: Val S. Goodfellow, Thong X. Nguyen, Satheesh B. Ravula, Harris A. Gelbard
-
Patent number: 9370515Abstract: Provided herein are imidazopyridine compounds having an inhibitory effect on mixed lineage kinases (MLKs), methods of their synthesis, and methods of their therapeutic. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions.Type: GrantFiled: March 7, 2014Date of Patent: June 21, 2016Assignees: CALIFIA BIO, INC., UNIVERSITY OF ROCHESTERInventors: Val S. Goodfellow, Thong X. Nguyen, Satheesh B. Ravula, Harris A. Gelbard
-
Publication number: 20160024031Abstract: Heterocyclic compounds are described that are lysophosphatidic acid receptor ligands that are useful in the treatment of lysophosphatidic acid receptor-dependent diseases and conditions, including but not limited to diseases involving fibrosis, such as fibrosis of the heart, kidney, liver and lung, and scleroderma; inflammatory diseases such as diabetic nephropathy and inflammatory bowel disease; ocular diseases such as diseases involving retinal degeneration; nerve diseases such as pruritus and pain. Non-limiting examples of those compounds include (RS)-3-Cyclopropyl-2-{4-[3-methyl-4((R)-1-phenyl-ethoxycarbonylamino)-isoxazol-5-yl]-benzyloxy}-propionic acid and (R)-1-(4?-{5-[1-(2-Chloro-phenyl)-ethoxycarbonylamino]-4-fluoro-pyrazol-1-yl}-2-fluoro-biphenyl-4-yl)-cyclopropanecarboxylic acid.Type: ApplicationFiled: March 17, 2014Publication date: January 28, 2016Applicant: EPIGEN BIOSCIENCES, INC.Inventors: Graham BEATON, Fabio C. TUCCI, Satheesh B. RAVULA, Chandravadan R. SHAH, Hiep LUU
-
Publication number: 20140256733Abstract: Provided herein are imidazopyridine compounds having an inhibitory effect on mixed lineage kinases (MLKs), methods of their synthesis, and methods of their therapeutic. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and pharmaceutical compositions.Type: ApplicationFiled: March 7, 2014Publication date: September 11, 2014Applicant: Califia Bio, Inc.Inventors: VAL S. GOODFELLOW, THONG X. NGUYEN, SATHEESH B. RAVULA, HARRIS A. GELBARD